Aligos Therapeutics, Inc. (ALGS) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Revenue Growth ALGS has had growing revenue for the last 2 years
Price to Book (PBV) Ratio Undervalued price-to-book. ALGS stock price is under 1x the price-to-book value.
Debt-Equity Ratio (DER) ALGS equity is higher than it's debt.

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Net Income Growth ALGS has never had growing net income.
Net Income ALGS never has positive net income for 2 years.
Dividend Yield ALGS has low dividend yield (0%).
Return of Assets ALGS has low return of asset (-68.19%).
Return of Equity ALGS has low return of equity (-75.01%).
Revenue ALGS never has positive revenue for 2 years.
Return of Invested Capital ALGS has low ROIC.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

-116,554,000 USD

Dividend

Financial Ratios

CEO

CEO Name

Dr. Lawrence M. Blatt

Management

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Additional Information

Company name

Aligos Therapeutics, Inc.

Symbol

NASDAQ:ALGS

Exchange

NASDAQ Global Select

Industry

Biotechnology

Sector

Healthcare

Address

One Corporate Drive
South San Francisco
CA
US
94080

Website

https://www.aligos.com